top of page

FDA Roundup: April 9, 2024

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: U.S. Food and Drug Administration 09 Apr, 2024, 15:31 ET On Friday, the FDA authorized for marketing MMI North America, Inc.’s Symani Surgical System, indicated for use during certain microsurgical procedures on small blood vessels and lymphatic ducts in adults. The system includes the use of a motion scaling function, which scales down the surgeon’s movements. Microsurgery covers procedures involving the use of microscopes and small instruments to perform small-scale surgical techniques. The system is intended for use by trained physicians in the operating environments described in the device’s labeling. On Friday, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. View full prescribing information for Enhertu

Aktuelle Beiträge

Alle ansehen

Appell des 44. DPT an Lauterbach

Zum Auftakt des 44. Deutschen Psychotherapeutentages (DPT), der am 12. und 13. April in Würzburg stattfindet, richten die Delegierten einen Appell an Bundesgesundheitsminister Prof. Dr. Lauterbach, di

Antiviral defense with new CRISPR tool

As the world prepares for future and ongoing global health threats from RNA viruses such as the SARS-CoV-2 pandemic, breakthrough advances in antiviral development are becoming a critical weapon in th


bottom of page